Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1031-1042

  Van Den Hoogen, Martijn W F ^a   Hoitsma, Andries J ^a   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alemtuzumab; antithymocyte globulin; kidney transplantation; rejection; renal transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; OKT 3; PREDNISONE; STEROID; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; TOL 101; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHILL; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DIARRHEA; DRUG MEGADOSE; DYSPNEA; FEVER; GRAFT FAILURE; GRAFT SURVIVAL; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY PARENCHYMA; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LUNG EDEMA; LYMPHATIC LEUKEMIA; MEDLINE; META ANALYSIS (TOPIC); MONONUCLEAR CELL; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PAIN; PILOT STUDY; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; THYROID DISEASE; VOMITING;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; COMMUNICABLE DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES; TREATMENT OUTCOME;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 84863791637     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.689278     Document Type: Review

References (77)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351(26):2715-29
3. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010;363(15):1451-62
4. Dierselhuis M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplant 2009;14(4):419-25
5. Wasowska BA. Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res 2010;47(1-3):25-44
6. Thaunat O, Nicoletti A. Lymphoid neogenesis in chronic rejection. Curr Opin Organ Transplant 2008;13(1):16-19
7. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55(2):713-23
8. Uslu A, Nart A. Treatment of first acute rejection episode: Systematic review of level I evidence. Transplant Proc 2011;43(3):841-6
9. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67(7):1011-18
10. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: A systematic review of randomized trial data. Transplantation 2006;81(7):953-65
11. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003;30(4):424-33
12. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006;26(12):1771-83
13. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006;82(11):1387-95
14. Midtvedt K, Fauchald P, Lien B, et al. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 2003;17(1):69-74
15. Clark KR, Forsythe JL, Shenton BK, et al. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int 1993;6(1):18-21
16. Delmonico FL, Nelson PW, Colvin RB, Cosimi AB. Immunologic monitoring of antithymocyte globulin treatment for acute allograft rejection. Transplant Proc 1984;16(6):1492-3
17. Cosimi AB, Wortis HH, Delmonico FL, Russell PS. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: Importance of T cell monitoring. Surgery 1976;80(2):155-63
18. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63(12):1229-43
19. Friend PJ, Hale G, Waldmann H, et al. Campath-1M-prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation 1989;48(2):248-53
20. Rai K, Hallek M. Future prospects for alemtuzumab (MabCampath). Med Oncol 2002;19(Suppl):S57-63
21. Clatworthy MR, Sivaprakasam R, Butler AJ, Watson CJ. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation 2007;84(12):1563-7
22. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006;81(1):81-7
23. Scarsi M, Bossini N, Malacarne F, et al. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients. Transpl Int 2010;23(8):786-95
24. Cantarovich D, LeMauff B, Hourmant M, et al. Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft-a pilot study. Transplantation 1989;47(3):454-7
25. Shield CF III, Cosimi AB, Tolkoff-Rubin N, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979;28(6):461-4
26. Hoitsma AJ, van Lier HJ, Reekers P, Koene RA. Improved patient and graft survival after treatment of acute rejections of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation 1985;39(3):274-9
27. Theodorakis J, Schneeberger H, Illner WD, et al. Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Transpl Int 1998;11(Suppl 1):S86-9
28. Glass NR, Miller DT, Sollinger HW, Belzer FO. A Comparative-Study of Steroids and Heterologous Anti-Serum in the Treatment of Renal-Allograft Rejection. Transplant Proc 1983;15(1):617-21
29. KDIGO. Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
30. Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: Long-term follow-up. Transplantation 2009;87(7):1092-5
31. Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005;37(2):923-6
32. Hesse UJ, Wienand P, Baldamus C, Arns W. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period. Transplant Proc 1990;22(5):2273-4
33. Mariat C, Alamartine E, Diab N, et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 1998;11(3):231-6
34. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant 2004;18(6):759-61
35. Csapo Z, avides-Viveros C, Podder H, Pollard V, Kahan BD. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 2005;37(5):2032-6
36. Upadhyay K, Midgley L, Moudgil A. Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection. Pediatr Transplant 2011;16(3):286-93
37. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation. Eur J Immunol 1990;20(3):509-15
38. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011;364(20):1909-19
39. Popow I, Leitner J, Majdic O, et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation 2012;93(1):32-40
40. Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R. Total and active thymoglobulin levels: Effects of dose and sensitization on serum concentrations. Transpl Immunol 2001;9(1):29-36
41. Prin Mathieu C, Renoult E, Kennel De March A, et al. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. Nephrol Dial Transplant 1997;12(10):2133-9
42. Regan J, Campbell K, van Smith L, et al. Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. Transpl Immunol 1997;5(1):49-56
43. Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA. Antithymocyte globulin hypersensitivity in bone marrow failure patients. JAMA 1988;260(21):3164-7
44. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104(4):948-55
45. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 1995;38(9):1187-93
46. Schnitzer TJ, Yocum DE, Michalska M, et al. Subcutaneous administration of CAMPATH-1H: Clinical and biological outcomes. J Rheumatol 1997;24(6):1031-6
47. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77(6):573-9
48. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006;6(5 Pt 1):1084-5
49. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119(7):2052-61
50. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008;8(7):1480-5
51. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44(2):204-12
52. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76(9):1289-93
53. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4(1):87-93
54. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80(9):1233-43
55. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-long-term results. Am J Transplant 2005;5(10):2539-48
56. Muthusamy AS, Vaidya AC, Sinha S, et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant 2008;8(10):2126-31
57. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-25
58. Toso C, Edgar R, Pawlick R, et al. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009;22(2):182-91
59. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002;100(5):1715-20
60. Zhang PL, Pennington JR, Prichard JW, et al. CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis. Ann Clin Lab Sci 2007;37(2):148-51
61. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006;6(6):478-83
62. Brett S, Baxter G, Cooper H, et al. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88(1):13-19
63. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008;8(10):1972-81
64. Siemenow M, Brown SA, Thompson JS, Miller SD, Getts DR. TOL101; a novel alphabeta TCR targeting monoclonal antibody. Am J Transplant 2010;10:36
65. Getts DR, Wiseman AC, Mulgaonkar S, et al. Evaluating safety and efficacy of TOL101 induction to prevent kidney transplant rejection, part a interim analysis. Transpl Int 2011;24:93
66. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378(9790):487-97
67. Bach JF. Anti-CD3 antibodies for type 1 diabetes: Beyond expectations. Lancet 2011;378(9790):459-60
68. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3(1):76-99
69. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62
70. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005;331(7520):810
71. Cai J, Terasaki PI. The current trend of induction and maintenance treatment in patient of different PRA levels: A report on OPTN/UNOS kidney Transplant Registry data. Clin Transpl 2010;45-52
72. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517
73. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205(13):3133-44
74. Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol 2009;9(11):811-16
75. Hester J, Mills N, Shankar S, et al. Th17 cells in alemtuzumab-treated patients: The effect of long-term maintenance immunosuppressive therapy. Transplantation 2011;91(7):744-50
76. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17(10):2844-53
77. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase De novo in kidney transplant patients after immunodepletion with campath-1H. Am J Transplant 2008;8(4):793-802